evitria AG is a Swiss biotechnology company headquartered near Zurich that specializes in CHO-based transient expression of antibodies, including bispecific and fusion antibodies, and other proteins for biopharmaceutical research and development.
Founded in 2010, evitria provides custom antibody production services to academic, emerging biotech and large biopharma customers worldwide. It is part of the Atlas Life Sciences Group owned by Patricia Industries. In July 2026, the company partnered with Evonik to launch the eviCHO Expression Kit, a ready-to-use transient protein expression system based on CHO-K1 cells.
None yet. When a new project in the record names evitria as owner, partner or investor, it shows here.
Ready-to-use CHO‑K1 transient expression kit simplifies lab workflows and speeds consistent protein production for early-stage biologics research.
